Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:40:31 2024-07-16 EDT			5-day change	1st Jan Change
1,185 ^INR	-0.27%		+1.66%	+71.91%

09:59am	Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India	MT
09:28am	Zydus Lifesciences Limited Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceutical Company for `Vault®' in India	CI

Cadila Healthcare Limited acquired eight brands from AstraZeneca India Pvt. Limited.

January 19, 2017

Cadila Healthcare Limited (BSE:532321) acquired eight brands from AstraZeneca India Pvt. Limited on January 20, 2017. Cadila Healthcare Limited (BSE:532321) completed the acquisition of eight brands from AstraZeneca India Pvt. Limited on January 20, 2017.

Latest news about Zydus Lifesciences Limited

Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India	03:59am	MT
Zydus Lifesciences Limited Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceutical Company for `Vault®' in India	03:28am	CI
Zydus Lifesciences Gets US FDA's Tentative Approval for Generic Multiple Sclerosis Drug	07-10	MT
Zydus Lifesciences Gets US FDA's Final Nod for Sacubitril, Valsartan Tablets	07-10	MT
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg	07-10	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Sacubitril and Valsartan Tablets	07-10	CI
Zydus Lifesciences Gets US FDA's Tentative Approval for Generic Hypertension Drug; Shares Up 4%	07-04	MT
Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg	07-04	CI
Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India	06-28	MT
Zydus and Dr. Reddy's Announces Licensing Agreement for Co-Marketing of Pertuzumab Biosimilar, a Critical Treatment for Breast Cancer Patients in India	06-28	CI
Zydus Lifesciences Gets US FDA's Tentative Approval for Generic Hypertension Drug	06-14	MT
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Azilsartan Medoxomil and Chlorthalidone Tablets	06-14	CI
India's pharma export sales to grow faster this year, trade body says	05-30	RE
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research	05-27	RE
Zydus Completes Patient Enrolment for Phase II Clinical Trial of Usnoflast in ALS Patients	05-24	MT
Zydus Lifesciences Limited Announces Completion of Enrolment for Phase II Clinical Trial of Usnoflast, Novel Oral Nlrp3 Inflammasome Inhibitor in Patients with Amyotrophic Lateral Sclerosis	05-24	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Theophylline Extended-Release Tablets, 300 Mg and 450 Mg	05-22	CI
Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988	05-21	MT
Zydus Lifesciences Records Sharp Rise in Fiscal Q4 Consolidated Profit	05-21	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,070 From INR750, Keeps at Hold	05-20	MT
Transcript : Zydus Lifesciences Limited, Q4 2024 Earnings Call, May 17, 2024	05-17
Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024	05-17	CI
Zydus Lifesciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-17	CI
Zydus Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-17	CI
Zydus Lifesciences Gets US FDA Nod to Market Dexamethasone Tablets	05-12	MT

Chart Zydus Lifesciences Limited

Duration

Period

More charts

Company Profile

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Sector

Pharmaceuticals

Calendar

2024-07-25 - Détachement de for final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for Zydus Lifesciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,185 INR

Average target price

1,029 INR

Spread / Average Target

-13.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.27B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.35B
OTSUKA HOLDINGS CO., LTD.	+38.38%	24.34B
SANDOZ GROUP AG	+27.09%	16.51B
CIPLA LIMITED	+21.19%	14.6B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.63%	6.57B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.08%	5.76B
STADA ARZNEIMITTEL	-8.87%	5.73B
KRKA, D. D.	+35.45%	5.01B

Generic Pharmaceuticals

Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Cadila Healthcare Limited acquired eight brands from AstraZeneca India Pvt. Limited.

EPS Revisions